Amicus Spins Out Rare Disease Gene Therapy Pipeline, Raises $200m

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.

Empty dirt road which splits in two, concept for life choices or decisions
Amicus will split out its gene therapy R&D into Caritas

Amicus Therapeutics, Inc. is spinning out its rare disease gene therapy portfolio into a separate publicly traded company and using the increasingly popular special purpose acquisition corporation (SPAC) model to do so. The Philadelphia-area biotech announced the deal, a separate financing and acceptance of a US regulatory filing for its combination product for Pompe disease during an investor call on 29 September.

In the fourth Arya Sciences SPAC transaction managed by Perceptive Advisors, the gene therapy pipeline compiled by Amicus via its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.